文献速递骨软组织肉瘤与黑色素瘤

吉西他滨联合西罗莫司治疗复发进展骨肉瘤的II期试验

Gemcitabine plus sirolimus for relapsed and progressing osteosarcoma patients after standard chemotherapy: a multicenter, single-arm phase II trial of Spanish Group for Research on Sarcoma (GEIS).
PubMed 文献 · Ann Oncol · 2017-01-01

主要终点4个月无进展生存率为44%,超过预设40%活性阈值;常见3-4级不良事件为中性粒细胞减少(37%)等,仅3例发热性中性粒细胞减少。

要点

  • 4个月PFSR为44%,超过预设40%的活性阈值。
  • 33例可评估患者中2例部分缓解、14例疾病稳定(48.5%)。
  • RRM1阳性与更差PFS和OS显著相关,P-ERK1/2阳性与显著更好OS相关。

核心结论

  • 吉西他滨联合西罗莫司在该骨肉瘤人群中显示出令人满意的抗肿瘤活性和安全性,4个月PFSR超过预设的40%。
  • 生物标志物与临床结局的显著相关性鼓励进一步前瞻性研究。

研究设计与样本

  • 多中心、单臂II期试验,由西班牙肉瘤研究组(GEIS)申办。
  • 治疗方案为吉西他滨联合口服西罗莫司5 mg/天,吉西他滨给药当天及前一天除外。
  • 主要终点为4个月无进展生存率(PFSR),预设高于40%视为活性方案。

主要发现

  • 4个月PFSR为44%。
  • 33例可评估患者中,经中心影像学评估,2例部分缓解,14例疾病稳定(48.5%)。
  • 最常见的3-4级不良事件为中性粒细胞减少(37%)、血小板减少(20%)、贫血(23%)和乏力(15%);仅3例发生发热性中性粒细胞减少。
  • RRM1蛋白表达阳性与更差的无进展生存和总生存显著相关。
  • P-ERK1/2阳性与显著更好的总生存相关。

关键数值与推荐

  • 4个月PFSR为44%,超过预设的40%活性阈值。
  • 33例可评估患者中2例部分缓解、14例疾病稳定(48.5%)。
  • 3-4级中性粒细胞减少发生率37%,血小板减少20%,贫血23%,乏力15%。

临床怎么用

  • 对于标准化疗后复发或进展且不适合转移灶切除的骨肉瘤患者,吉西他滨联合西罗莫司可作为候选治疗方案。
  • 治疗期间需关注中性粒细胞减少、血小板减少、贫血和乏力等3-4级不良事件。
  • RRM1和P-ERK1/2表达状态可能与预后相关,但需进一步前瞻性研究验证。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with relapsed unresectable osteosarcoma represents an unmet need, so active and safe systemic treatments are required. Fas cell surface death receptor and mammalian target of rapamycin pathways are implicated in progressing osteosarcoma, and we had preclinical and clinical experience with a scheme that targets both pathways. Therefore, we designed a phase II trial with gemcitabine plus rapamycin, to determine the efficacy and safety, in this subset of patients. PATIENTS AND METHODS: A multicenter, single-arm phase II trial was sponsored by the Spanish Group for Research on Sarcoma. Osteosarcoma patients, relapsed or progressing after standard chemotherapy and unsuitable for metastasectomy received gemcitabine and rapamycin p.o. 5 mg/day except for the same day of gemcitabine administration, and the day before. The main end point was 4-month progression-free survival rate (PFSR), with the assumption that rates higher than 40% would be considered as an active regimen. Translational research aimed to correlate biomarkers with the clinical outcome. RESULTS: Thirty-five patients were enrolled and received at least one cycle. PFSR at 4 months was 44%, and after central radiologic assessment, 2 partial responses and 14 stabilizations (48.5%) were reported from 33 assessable patients. The most frequent grade 3-4 adverse events were: neutropenia (37%), thrombocytopenia (20%), anemia (23%), and fatigue (15%); however, only three patients had febrile neutropenia. Positive protein expression of RRM1 significantly correlated with worse PFS and overall survival, while positivity of P-ERK1/2 was correlated with significant better overall survival. CONCLUSION: Gemcitabine plus sirolimus exhibits satisfactory antitumor activity and safety in this osteosarcoma population, exceeding the prespecified 40% of 4-month PFSR. The significant correlation of biomarkers with clinical outcome encourages further prospective investigation.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Martin-Broto J, Redondo A, Valverde C, et al. Gemcitabine plus sirolimus for relapsed and progressing osteosarcoma patients after standard chemotherapy: a multicenter, single-arm phase II trial of Spanish Group for Research on Sarcoma (GEIS). Ann Oncol. 2017. PMID: 29045512. doi:10.1093/annonc/mdx536

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。